3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Colonic Neoplasms
10
Colorectal Neoplasms
8
Postoperative Complications
2
Anastomotic Leak
2
Transfusion Reaction
1
Sarcopenia
1
Peritoneal Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Metabolomics
1
Intestinal Perforation
1
Ileus
1
Emergencies
1
Diverticulosis, Colonic
1
Diverticulitis
1
Cholecystolithiasis
1
Carcinoma, Hepatocellular
1
Appendiceal Neoplasms
1
Interventions
lutetium Lu 177 dotatate
29
Everolimus
19
Temozolomide
11
gallium Ga 68 dotatate
10
Nivolumab
10
Magnetic Resonance Spectroscopy
10
Capecitabine
9
pembrolizumab
8
lanreotide
8
Positron Emission Tomography Computed Tomography
8
cabozantinib
7
3-Iodobenzylguanidine
7
177Lu-octreotide, DOTA(0)-Tyr(3)-
7
Somatostatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
telotristat ethyl
5
lenvatinib
5
Octreotide
5
Lutetium-177
5
Ga(III)-DOTATOC
5
Fluorodeoxyglucose F18
5
Carboplatin
5
avelumab
4
Positron-Emission Tomography
4
Ipilimumab
4
Bevacizumab
4
surufatinib
3
pasireotide
3
fluorodopa F 18
3
copper dotatate CU-64
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neuroendocrine Tumors
×
Colectomy
×
Clear all
NCT04735198
2025-05-20
TNE-IDC-COLE
Hospital Universitari de Bellvitge
Phase NA
Recruiting
100 enrolled